Dr. Hausman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1616 Eastlake
1616 Eastlake Ave E
Seattle, WA 98102Phone+1 206-372-2943
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 1992 - 1995- University of WashingtonResidency, Internal Medicine, 1989 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1989
Certifications & Licensure
WA State Medical License 1991 - 2025
Clinical Trials
- Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer Start of enrollment: 2004 May 01
- Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection Start of enrollment: 2007 Dec 01
- Phase 1 and 2 Study of PX-866 and Cetuximab Start of enrollment: 2010 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 89 citationsPhase II study of PX-866 in recurrent glioblastomaMarshall Pitz, Elizabeth Eisenhauer, Mary MacNeil, Brian Thiessen, Jacob C. Easaw
Neuro-Oncology. 2015-09-01 - 7 citationsPeginterferon Lambda-1a, a New Therapeutic for Hepatitis C Infection, from Bench to Clinic.Henrik Andersen, Jeffrey D Meyer, Jeremy Freeman, Sean Doyle, Kevin M. Klucher
Journal of Clinical and Translational Hepatology. 2013-12-28 - 130 citationsA Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid TumorsDavid S. Hong, Daniel W. Bowles, Gerald S. Falchook, Wells A. Messersmith, Goldy C. George
Clinical Cancer Research. 2012-08-01
Press Mentions
Riding Success of Roche-Partnered Lung Cancer Drug, Blueprint Makes $250M Play for Lengo's Preclinical WorkNovember 29th, 2021- Two Months After Inking a SPAC Deal, Renovacor Taps New CMO; CureVac Reels in a New Development Chief from Merck KGaAJune 4th, 2021
- Chutes & Ladders—Repertoire Immune Medicines, Buzzing from $189M Series B, Taps Celgene Vet as CMOJune 4th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
